Ignite Creation Date:
2024-05-06 @ 9:57 AM
Last Modification Date:
2024-10-26 @ 12:22 PM
Study NCT ID:
NCT03129867
Status:
COMPLETED
Last Update Posted:
2023-01-12
First Post:
2017-04-21
Brief Title:
ADHerence of ticagrelOr in Real World Patients With aCute Coronary Syndrome
Sponsor:
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Organization:
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Study Overview
Official Title:
Incidence and Models of Ticagrelor Discontinuation in Patients With Acute Coronary Syndrome
Status:
COMPLETED
Status Verified Date:
2023-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
AD-HOC
Brief Summary:
Ticagrelor 90 mg twice daily treatment is recommended for 12 months in patients with acute coronary syndrome ACS and in patients undergoing coronary revascularization and conservative strategies Recent data from the PEGASUS-TIMI 541 trial have shown that long-term treatment with ticagrelor reduced the risk of major cardiovascular adverse events MACE in stable ambulatory patients with a history of myocardial infarction Based on these data prolongation over 12 months of ticagrelor therapy could be indicated in selected patients even if with such a prolongation some adverse effects on the treatment could be observed In the PLATO2 trial where median duration of exposure to the study drug was 277 days the suspension of ticagrelor therapy was 74 in ticagrelor versus 6 in patients receiving clopidogrel P 0001 Ticagrelor treatment interruption was mainly driven by non-serious adverse events occurring mainly shortly after randomization For patients after the first year of treatment the subsequent rate of interruption was low These data demonstrate that adverse events considered not serious by traditional trial criteria may have an effect on quality of life and therefore can cause treatment interruption The phenomenon emphasizes at the same time the importance of patient education and advice on timing and the nature of adverse effects in order to improve adherence Patients in the real world may show a premature suspension rate of the drug even higher than in clinical trials However data from real-world patients is scarce
Detailed Description:
Ticagrelor 90 mg twice daily treatment is recommended for 12 months in patients with acute coronary syndrome ACS and in patients undergoing coronary revascularization and conservative strategies Prolongation over 12 months of ticagrelor therapy could be indicated in selected patients even if with such a prolongation some adverse effects on the treatment could be observed In the PLATO2 trial where median duration of exposure to the study drug was 277 days the suspension of ticagrelor therapy was 74 in ticagrelor versus 6 in patients receiving clopidogrel P 0001 Ticagrelor treatment interruption was mainly driven by non-serious adverse events occurring mainly shortly after randomization For patients after the first year of treatment the subsequent rate of interruption was low These data demonstrate that adverse events considered not serious by traditional trial criteria may have an effect on quality of life and therefore can cause treatment interruption The phenomenon emphasizes at the same time the importance of patient education and advice on timing and the nature of adverse effects in order to improve adherence Patients in the real world may show a premature suspension rate of the drug even higher than in clinical trials However data from real-world patients is scarce
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None